Akers Biosciences, Inc.

129 articles with Akers Biosciences, Inc.

• Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

  4/16/2021

  Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol " MYMD " Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1

• Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial

  4/13/2021

  Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19.

• Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board

  4/12/2021

  Akers Biosciences, Inc., announced that its proposed merger partner MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board.

• Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals

  3/22/2021

  Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER202

• MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery

  2/23/2021

  Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.

• Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission

  2/18/2021

  Findings of study published in PLOS One found a highly significant correlation between temperature and the rate of increase in COVID-19

• Akers Biosciences Responds to Erroneous Earnings Call Press Release

  2/17/2021

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name.

• AKERS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Akers Biosciences, Inc. - AKER

  12/3/2020

  Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Biosciences, Inc. (NasdaqCM: AKER) with MyMD Pharmaceuticals, Inc., pursuant to which Akers shareholders will end up owning just 20% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the

• Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent

  12/2/2020

  Patent protects methods of regulating TNF-α to treat cancers, autoimmune disorders, and other disorders associated with chronic inflammation

• REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals

  11/18/2020

  MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications. To

• Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results

  8/27/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice.

• Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  8/11/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,207,744 shares of the Company’s common stock, at a purchase price of $5.67 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

• Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies

  7/7/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, the initiation of animal studies for its SARS-CoV-2 vaccine candidate in India. Premas has successfully completed the manufacturing process for the VLP (virus like particle) vaccine candidate, including th

• Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  5/18/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules.

• Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  5/14/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share,

• Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP

  5/14/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype. Premas obtained transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast during the pas

• Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens

  4/8/2020

  Akers Biosciences, Inc. , today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-Crypt TM platform at Prema

• Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  4/7/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules

• Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

  4/6/2020

  Successfully obtained clones for all three selected Coronavirus Antigens

• 

  Biopharma Industry News for March 24: Update on the Novel Coronavirus

  3/24/2020

  A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.